Comparing Trastuzumab and ERBB2 Downregulation in Breast Cancer Treatment
Author Information
Author(s): Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn L C, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller G A, Mössner J, Bauer A, Schiffer I B, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler J G
Primary Institution: Leibniz Research Centre for Working Environment and Human Factors, University of Dortmund
Hypothesis
Can ERBB2 downregulation provide better tumor remission compared to trastuzumab therapy in ERBB2-dependent tumors?
Conclusion
ERBB2 downregulation leads to complete tumor remission, while trastuzumab shows only a weak effect despite ERBB2 dependence.
Supporting Evidence
- ERBB2 downregulation led to a macroscopically complete tumor remission within 14 days.
- Trastuzumab caused only a slight decrease in tumor proliferation.
- Trastuzumab increased phosphorylated AKT levels significantly.
- Downregulation of ERBB2 resulted in a strong decrease in Ki-67 positive nuclei.
Takeaway
In a study with mice, stopping the production of a cancer-related protein called ERBB2 made tumors go away quickly, but a medicine called trastuzumab didn't work as well even though it was supposed to help.
Methodology
Mice with ERBB2-dependent tumors were treated with either anhydrotetracycline (ATc) or trastuzumab, and tumor growth was measured.
Potential Biases
Potential bias due to the use of a single mouse model and lack of human data.
Limitations
The study was conducted in a mouse model, which may not fully represent human responses.
Participant Demographics
Male nude mice aged 3-4 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website